Literature DB >> 19574249

Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells.

Joo-Yun Byun1, Min-Jung Kim, Da-Young Eum, Chang-Hwan Yoon, Woo-Duck Seo, Ki Hun Park, Jin-Won Hyun, Yun-Sil Lee, Jae-Seong Lee, Moon-Young Yoon, Su-Jae Lee.   

Abstract

Naturally occurring triterpenoid compounds have long been used as anti-inflammatory, antimalarial, and insecticidal agents. It has become evident that some of the natural or synthetic triterpenoids have promising clinical potential as both a therapeutic and chemopreventive agent for cancer. However, the molecular basis for the antitumor activity of triterpenoid has yet to be defined. In this study, we show that pristimerin, a natural triterpenoid, induces mitochondrial cell death in human cervical cancer cells and that reactive oxygen species (ROS)-dependent activation of both Bax and poly(ADP-ribose) polymerase-1 (PARP-1) is critically required for the mitochondrial dysfunction. We also showed that c-Jun N-terminal kinase (JNK) is involved in ROS-dependent Bax activation. Treatment of pristimerin induced an increase in intracellular ROS, JNK activation, conformational change, and mitochondrial redistribution of Bax, mitochondrial membrane potential loss, and cell death. The PARP-1 was also found to be activated by pristimerin treatment. An antioxidant, N-acetyl-l-cysteine (NAC), inhibited pristimerin-induced JNK activation, Bax relocalization, and PARP-1 activation, as well as mitochondrial cell death. Moreover, inhibition of JNK clearly suppressed conformational change and mitochondrial translocation of Bax and subsequent mitochondrial cell death but did not affect PARP-1 activation. Inhibition of PARP-1 with 1,5-dihydroxyisoquinoline (DIQ) or with small interfering RNA of PARP-1 significantly attenuated pristimerin-induced mitochondrial membrane potential loss and cell death but did not affect JNK activation and Bax relocalization. These results indicate that the natural triterpenoid pristimerin induces mitochondrial cell death through ROS-dependent activation of both Bax and PARP-1 in human cervical cancer cells and that JNK is involved in ROS-dependent Bax activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574249     DOI: 10.1124/mol.109.056259

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  29 in total

1.  Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway.

Authors:  Ji Hye Kim; Byoungduck Park; Subash C Gupta; Ramaswamy Kannappan; Bokyung Sung; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2011-12-15       Impact factor: 8.401

2.  Pristimerin induces apoptosis of oral squamous cell carcinoma cells via G1 phase arrest and MAPK/Erk1/2 and Akt signaling inhibition.

Authors:  Haiyan Wu; Long Li; Zhengdong Ai; Jingyi Yin; Li Chen
Journal:  Oncol Lett       Date:  2019-01-08       Impact factor: 2.967

3.  PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells.

Authors:  Xiaohui Zhu; Li Chen; Sheng Jiang; Chun Chen; Yiwu Yao; Dong Chen; Hongman Xue; Jingxuan Pan
Journal:  Cancer Biol Ther       Date:  2013-11-19       Impact factor: 4.742

Review 4.  Targeting tumor proteasome with traditional Chinese medicine.

Authors:  Huanjie Yang; Jinbao Liu; Q Ping Dou
Journal:  Curr Drug Discov Technol       Date:  2010-03

5.  Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR signaling.

Authors:  Xiaohua Gao; Yongbo Liu; Dorrah Deeb; Ali S Arbab; Subhash C Gautam
Journal:  J Exp Ther Oncol       Date:  2014

6.  The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction.

Authors:  Yan-Yan Yan; Jian-Ping Bai; Yong Xie; Jie-Zhong Yu; Cun-Gen Ma
Journal:  Oncol Lett       Date:  2012-10-22       Impact factor: 2.967

7.  Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling.

Authors:  Gui'e Xie; Xinpei Yu; Huichao Liang; Jingsong Chen; Xuewei Tang; Shaoqing Wu; Can Liao
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967

8.  PARP1-mediated necrosis is dependent on parallel JNK and Ca²⁺/calpain pathways.

Authors:  Diana L Douglas; Christopher P Baines
Journal:  J Cell Sci       Date:  2014-07-22       Impact factor: 5.285

9.  Pristimerin Induces Apoptosis in Prostate Cancer Cells by Down-regulating Bcl-2 through ROS-dependent Ubiquitin-proteasomal Degradation Pathway.

Authors:  Yong Bo Liu; Xiaohua Gao; Dorrah Deeb; Ali S Arbab; Subhash C Gautam
Journal:  J Carcinog Mutagen       Date:  2013-11-05

10.  Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.

Authors:  Yongwei Wang; Yinan Zhou; Haoxin Zhou; Guang Jia; Ji Liu; Bing Han; Zhuoxin Cheng; Hongchi Jiang; Shangha Pan; Bei Sun
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.